tbuckley/cabot-search huggingface dataset:
Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression
Authors: Patricia Dauer, Xianda Zhao, Vineet K. Gupta, Nikita Sharma, Kousik Kesh, Prisca Gnamlin, Vikas Dudeja, Selwyn M. Vickers, Sulagna Banerjee, Ashok Saluja
Journal: Cancer Research (2017)

Abstract Resident fibroblasts that contact tumor epithelial cells (TEC) can become irreversibly activated as cancer-associated-fibroblasts (CAF) that stimulate oncogenic signaling in TEC. In this study, we evaluated the cross-talk between CAF and TEC isolated from tumors generated in a mouse model of KRAS/mut p53-induced pancreatic cancer (KPC mice). Transcriptomic profiling conducted after treatment with the anticancer compound Minnelide revealed deregulation of the TGFβ signaling pathway in CAF, resulting in an apparent reversal of their activated state to a quiescent, nonproliferative state. TEC exposed to media conditioned by drug-treated CAFs exhibited a decrease in oncogenic signaling, as manifested by downregulation of the transcription factor Sp1. This inhibition was rescued by treating TEC with TGFβ. Given promising early clinical studies with Minnelide, our findings suggest that approaches to inactivate CAF and prevent tumor–stroma cross-talk may offer a viable strategy to treat pancreatic cancer. Significance: In an established mouse model of pancreatic cancer, administration of the promising experimental drug Minnelide was found to actively deplete reactive stromal fibroblasts and to trigger tumor regression, with implications for stromal-based strategies to attack this disease. Cancer Res; 78(5); 1321–33. ©2018 AACR.
Novel <i>POFUT1</i> mutation associated with hidradenitis suppurativa–Dowling–Degos disease firm up a role for Notch signalling in the pathogenesis of this disorder: reply from the authors
Authors: M. Pavlovsky, O. Sarig, M. Eskin-Schwartz, A. Hafner, E. Sprecher
Journal: British Journal of Dermatology (2017)
Benefits and Risks of Machine Learning Decision Support Systems
Authors: Alexander L. Fogel, Joseph C. Kvedar
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of the basophil response in patients with NSAID-exacerbated respiratory disease (NERD) after nasal provocation test with lysine-aspirin (NPT-LASA)
Authors: Jesus Verge, Miguel Gonzalez, Carmen M. Rondon Segovia, Inmaculada Dona, Tahia D. Fernandez, Ruben Fernandez, Jose A. Cornejo-Garcia, Cristobalina Mayorga, Maria J. Torres, Paloma Campo
Journal: Journal of Allergy and Clinical Immunology (2018)
Erratum: Corrigendum: Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
Authors: Timothy Kottke, Fiona Errington, Jose Pulido, Feorillo Galivo, Jill Thompson, Phonphimon Wongthida, Rosa Maria Diaz, Heung Chong, Elizabeth Ilett, John Chester, Hardev Pandha, Kevin Harrington, Peter Selby, Alan Melcher, Richard Vile
Journal: Nature Medicine (2012)
Targeting cell-bound MUC1 on myelomonocytic leukemias and leukemic stem cells: Therapeutic implications.
Authors: Daniel B. Rubinstein, Thierry Guillaume
Journal: Journal of Clinical Oncology (2016)

e14003 Background: Monocytic neoplasms,include chronic myelomonocytic leukemia (CMML), acute myelomonocytic and monocytic leukemia, and monocytic sarcoma. Cell surface molecules overexpressed by leukemic cells represent potential disease-specific therapeutic targets..MUC1 has an extracellular domain containing tandem repeats of a 20 amino acid-long sequence, a transmembrane domain, and a short cytoplasmic tail. Cleavage of MUC1 yields an extracellular alpha subunit containing the tandem repeat and a smaller beta subunit. Anti-MUC1 Abss reported to date target the highly immunogenic tandem repeat of the MUC1 alpha chain. However the alpha chain is cell-bound only intermittently to MUC1+ cells. In contrast, the MUC1 SEA domain remains fixed to the cell surface. Methods: A series of 22 AML samples (AML0 = 2, AML1 = 2, AML2 = 10, AML4 = 1, AML5 = 5, AML6 = 2) collected either at the time of diagnosis or at relapse were analysed for MUC1 expression by flow cytometry. A murine mammary tumor cell line transfected with MUC1 DNA served as control. Results: Blasts cells from 5 AML samples highly expressed MUC1, and all were of monocytic or myelomonocytic lineage (AML4 = 1, AML5 = 4). Leukemic stem cells (CD34pos or CD34neg linneg) from the MUC1+ AMLs expressed MUC1. AML cell lines MV411, MOLM14, and SHI-1 from monocytic leukemia clearly express surface MUC1, while non- monocytic leukemic cell lines U937, K562, and HL60 had little or no expression. Normal monocytes and monocytes derived from patients with activated monocytosis also express MUC1.In 15 CMML samples (type 1 n = 11, type 2 n = 4) , BM n = 7) 92%-100% (median 99.7%) of CD14+CD56+ CMML cells bound mAb DMB-5F3 to cell-surface MUC1. CD14+CD16+CD56+ blast cells from 2 pts with JMML also expressed MUC1 (64% to 71 % ). Conclusions: We conclude that expression of MUC1 is restricted to monocytic and myelomonocytic leukemias and that MUC1 represents an effective target for leukemic immunotherapy. Significantly, anti-MUC1 mAb also targets monocytic leukemic stem cells, reinforcing its therapeutic potential..anti-MUC1 Ab DMB-5F3 can enter cells and thereby ferry Ab-bound toxin opening the way for leukemic cell killing with anti-MUC1 mAb-immunotoxin conjugates.
Erratum: Synovial tissue research: a state-of-the-art review
Authors: Carl Orr, Elsa Vieira-Sousa, David L. Boyle, Maya H. Buch, Christopher D. Buckley, Juan D. Cañete, Anca I. Catrina, Ernest H. S. Choy, Paul Emery, Ursula Fearon, Andrew Filer, Danielle Gerlag, Frances Humby, John D. Isaacs, Søren A. Just, Bernard R. Lauwerys, Benoit Le Goff, Antonio Manzo, Trudy McGarry, Iain B. McInnes, Aurélie Najm, Constantino Pitzalis, Arthur Pratt, Malcolm Smith, Paul P. Tak, Rogier Thurlings, João E. Fonseca, Douglas J. Veale
Journal: Nature Reviews Rheumatology (2017)
Психологічна дезадаптація пацієнтів з ГЕРХ: огляд та власні дослідження
Authors: L.M. Mosiichuk, L.V. Demeshkina, I.V. Kushnirenko, I.Yu. Zavialova
Journal: GASTROENTEROLOGY (2014)

У статті наведені сучасні дані щодо психосоматичної проблеми у медицині, зокрема, світовий досвід вивчення порушень психологічної адаптації у хворих на гастроезофагеальну рефлексну хворобу (ГЕРХ), а також подані результати власних досліджень. За допомогою застосованих психологічних тестів частота виявлення тривожності та депресивності у пацієнтів із ГЕРХ становила 100 та 91,2 % відповідно. Дослідження, проведені у віддаленому періоді, свідчать, що наявність психологічної дезадаптації у пацієнтів із ГЕРХ унеможливлює досягнення стійкої ремісії щодо основного захворювання та вимагає відповідної корекції.
Outcomes Associated With Left Ventricular Assist Devices Among Recipients With and Without End-stage Renal Disease
Authors: Nisha Bansal, Susan M. Hailpern, Ronit Katz, Yoshio N. Hall, Manjula K. Tamura, William Kreuter, Ann M. O’Hare
Journal: JAMA Internal Medicine (2017)

Left ventricular assist devices (LVADs) are widely used both as a bridge to heart transplant and as destination therapy in advanced heart failure. Although heart failure is common in patients with end-stage renal disease (ESRD), little is known about outcomes after LVAD implantation in this population.To determine the utilization of and outcomes associated with LVADs in nationally representative cohorts of patients with and without ESRD.We described LVAD utilization and outcomes among Medicare beneficiaries after ESRD onset (defined as having received maintenance dialysis or a kidney transplant) from 2003 to 2013 based on Medicare claims linked to data from the United States Renal Data System (USRDS), a national registry for ESRD. We compared Medicare beneficiaries with ESRD to a 5% sample of Medicare beneficiaries without ESRD.ESRD (vs no ESRD) among patients who underwent LVAD placement.The primary outcome was survival after LVAD placement.Among the patients with ESRD, the mean age was 58.4 (12.1) years and 62.0% (96) were male. Among those without ESRD, the mean age was 62.2 (12.6) years and 75.1% (196) were male. From 2003 to 2013, 155 Medicare beneficiaries with ESRD (median and interquartile range [IQR] days from ESRD onset to LVAD placement were 1655 days [453-3050 days]) and 261 beneficiaries without ESRD in the Medicare 5% sample received an LVAD. During a median follow-up of 762 days (IQR, 92-3850 days), 127 patients (81.9%) with and 95 (36.4%) without ESRD died. more than half of patients with ESRD (80 [51.6%]) compared with 11 (4%) of those without ESRD died during the index hospitalization. The median time to death was 16 days (IQR 2-447 days) for patients with ESRD compared with 2125 days (IQR, 565-3850 days) for those without ESRD. With adjustment for demographics, comorbidity and time period, patients with ESRD had a markedly increased adjusted risk of death (hazard ratio, 36.3; 95% CI, 15.6-84.5), especially in the first 60 days after LVAD placement.Patients with ESRD at the time of LVAD placement had an extremely poor prognosis, with most surviving for less than 3 weeks. This information may be crucial in supporting shared decision-making around treatments for advanced heart failure for patients with ESRD.
Donor Lymphocyte Infusion Management and Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.
Authors: Mauricette Michallet, Quoc-Hung Le, Anne-Sophie Michallet, Anne Thiebaut, Emannuelle Tavernier, Hanadi Rafii, Daniela Revesz, Jacques Troncy, Aline Praire, Elodie Gadolet, Valerie Dubois, Lucette Gebuhrer, Olivier Hequet, Jean-Paul Bourgeot, Franck E. Nicolini
Journal: Blood (2004)
Abstract 13281: Racial, Gender, or Income Disparities Not Related to Outcomes in the First Year After an Implantable Cardioverter Defibrillator (ICD)
Authors: Cynthia M Dougherty, Carolyn M Reilly, Elaine A Thompson
Journal: Circulation (2016)

Introduction: Racial, gender, and income disparities among implantable cardioverter defibrillator (ICD) recipients have been widely reported. In particular, African Americans (AA), women, and those with lower socioeconomic status (SES) are less likely to receive an ICD or report poorer outcomes after ICD implant. The purpose of this study was to determine if racial, gender, or income disparities had an impact on number of ICD shocks or all cause hospitalization in the first year after initial ICD implant. Methods: 300 patients receiving an initial ICD in the Pacific NW were followed for 1 year. Patients were (mean±SD) 64±12 years old, 90% Caucasian, 4% AA, 2% Am Indian (AI), 2% Latino, 75% male, 87% living in urban areas, with 25% employed FT, 10% PT, and 43% retired, averaging $30-49K in household income. ICD shocks and hospitalizations were verified using medical records. Descriptive statistics, Chi 2 , and correlations were used to examine for health disparities in clinical outcomes over 1 year. Results: There were no significant associations between race, gender or SES and outcomes of ICD shock or all cause hospitalization within 1 year. For race , 10.7% of Caucasians and 0.7% of all other races received an ICD shock (X 2 =3.36, p=0.50); 28% of Caucasians, 2.7% of AA, 1.4% AI, and 0.7% Latino were hospitalized (X 2 =1.57, p=0.81). For gender , 3.4% of women and 9.5% of men received an ICD shock (X 2 =0.20, p=0.65); 4.7% of women and 29.1% of men were hospitalized (X 2 =3.0, p=0.08). For SES , 5.6% in $10-29K, 3.5% in $30-49K, and 2.1% in &gt;$90K received an ICD shock (X 2 =10.3, p=0.07); 6.9% in $10-29K, 11.8% in $30-49K, and 5.6% in &gt;$90K were hospitalized (X 2 =6.4, p=0.27). Results showed trends (p&lt;.10) of men more likely to be hospitalized and those with lower SES more likely to have ICD shocks in the first year. Conclusions: We found no statistically significant associations between patient race, gender or income and the incidence of ICD shocks or hospitalizations in the first year post-ICD implant. Other research reveals disparities with respect to who receives an ICD, but these findings reveal no differences in ICD-related outcomes once patients have received an ICD.
Design and Structure–Function Characterization of 3D Printed Synthetic Porous Biomaterials for Tissue Engineering
Authors: Cambre N. Kelly, Andrew T. Miller, Scott J. Hollister, Robert E. Guldberg, Ken Gall
Journal: Advanced Healthcare Materials (2017)

Abstract 3D printing is now adopted for use in a variety of industries and functions. In biomedical engineering, 3D printing has prevailed over more traditional manufacturing methods in tissue engineering due to its high degree of control over both macro‐ and microarchitecture of porous tissue scaffolds. However, with the improved flexibility in design come new challenges in characterizing the structure–function relationships between various architectures and both mechanical and biological properties in an assortment of clinical applications. Presently, the field of tissue engineering lacks a comprehensive body of literature that is capable of drawing meaningful relationships between the designed structure and resulting function of 3D printed porous biomaterial scaffolds. This work first discusses the role of design on 3D printed porous scaffold function and then reviews characterization of these structure–function relationships for 3D printed synthetic metallic, polymeric, and ceramic biomaterials.
Validation of the Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments
Authors: L Lee Dupuis, Donna L Johnston, Christina Baggott, Shannon Hyslop, Deborah Tomlinson, Paul Gibson, Andrea Orsey, David Dix, Vicky Price, Magimairajan Vanan, Carol Portwine, Susan Kuczynski, Brenda Spiegler, George A Tomlinson, Lillian Sung
Journal: JNCI Journal of the National Cancer Institute (2017)

The objective was to evaluate the reliability and validity of the self-report Symptom Screening in Pediatrics Tool (SSPedi) from the perspective of children with cancer and pediatric hematopoietic stem cell transplant (HSCT) recipients. In this multicenter study, respondents were children age eight to 18 years who had cancer or had received HSCT, and their parents. Two different child respondent populations were targeted. More symptomatic respondents were receiving active treatment for cancer, admitted to the hospital, and expected to be in the hospital three days later. Less symptomatic respondents were in maintenance therapy for acute lymphoblastic leukemia or had completed cancer therapy. Children completed SSPedi and then responded to validated self-report measures of mucositis, nausea, pain, and global quality of life. Children in the more symptomatic group repeated SSPedi and a global symptom change scale three days later. Parent proxy-report was optional. Reliability was evaluated using intraclass correlations while convergent validity was evaluated using Spearman correlations. Of 502 children enrolled, 302 were in the more symptomatic group and 200 were in the less symptomatic group. Intraclass correlation coefficients were 0.88 (95% confidence interval [CI] = 0.82 to 0.92) for test-retest reliability and 0.76 (95% CI = 0.71 to 0.80) for inter-rater reliability. The mean difference in SSPedi scores between more and less symptomatic groups was 7.8 (95% CI = 6.4 to 9.2). SSPedi was responsive to change in global symptoms. All hypothesized relationships among measures were observed. SSPedi is a self-report symptom bother tool for children with cancer and HSCT recipients that is reliable, valid, and responsive to change. SSPedi can be used for clinical and research purposes. Future work should focus on integration into care delivery.
Association of Timing of Weight Gain in Pregnancy With Infant Birth Weight
Authors: Ravi Retnakaran, Shi Wu Wen, Hongzhuan Tan, Shujin Zhou, Chang Ye, Minxue Shen, Graeme N. Smith, Mark C. Walker
Journal: JAMA Pediatrics (2017)

Gestational weight gain is a determinant of infant birth weight, but it is unclear whether its timing in pregnancy may hold implications in this regard. Previous studies have yielded conflicting findings on the association of maternal weight gain in early pregnancy with birth weight. However, as these studies have typically recruited women during the first trimester, they are inherently limited by a reliance on self-reported pregravid weight.To evaluate the associations of directly measured maternal pregravid weight and the timing of subsequent weight gain across pregnancy with infant birth weight.In this prospective, preconception, observational cohort study, 1164 newly married women in Liuyang, China, underwent pregravid evaluation at a median of 19.9 weeks before a singleton pregnancy during which they underwent serial weight measurements. The study was conducted from February 1, 2009, to November 4, 2015. Data analysis was performed between September 1, 2016, and May 6, 2017.Maternal weight gain was calculated for the following 10 gestational intervals: from pregravid to less than 14, 14 to 18, 19 to 23, 24 to 28, 29 to 30, 31 to 32, 33 to 34, 35 to 36, 37 to 38, and 39 to 40 weeks.Associations of pregravid weight and weight gain within each of the 10 gestational intervals with the outcome of infant birth weight.The mean (SD) age of the 1164 women included in the study was 25.3 (3.1) years. Pregravid weight was consistently associated with infant birth weight. However, among the 10 gestational intervals, only weight gain from pregravid to 14 weeks and from 14 to 18 weeks was associated with birth weight. Birth weight increased by 13.6 g/kg (95% CI, 3.2-24.1 g/kg) of maternal weight gain from pregravid to 14 weeks and by 26.1 g/kg (95% CI, 3.8-48.4 g/kg) of maternal weight gain from 14 to 18 weeks.Maternal weight only in the first half of gestation is a determinant of infant birth weight. Before pregnancy and early gestation may be a critical window for intervention to affect subsequent birth weight.
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
Authors: Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong, Janice P. Dutcher
Journal: Journal for ImmunoTherapy of Cancer (2017)

Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE reports related to high dose interleukin-2 therapy (IL-2) documented in the PROCLAIM
Prognostic Implications of Magnetic Resonance–Derived Quantification in Asymptomatic Patients With Organic Mitral Regurgitation
Authors: Martin Penicka, Jan Vecera, Daniela C. Mirica, Martin Kotrc, Radka Kockova, Guy Van Camp
Journal: Circulation (2017)

Magnetic resonance imaging (MRI) is an accurate method for the quantitative assessment of organic mitral regurgitation (OMR). The aim of the present study was to compare the discriminative power of MRI quantification and the recommended Doppler echocardiography (ECHO)-derived integrative approach to identify asymptomatic patients with OMR and adverse outcome.The study population consisted of 258 asymptomatic patients (63±14 years, 60% men) with preserved left ventricular ejection fraction (>60%) and chronic moderate and severe OMR (flail 25%, prolapse 75%) defined by using the ECHO-derived integrative approach. All patients underwent MRI to quantify regurgitant volume (RV) of OMR by subtracting the aortic forward flow volume from the total left ventricular stroke volume. Severe OMR was defined as RV≥60 mL.Mean ECHO-derived RV was on average 17.1 mL larger than the MRI-derived RV (P<0.05). Concordant grading of OMR severity with both techniques was observed in 197 (76%) individuals with 62 (31%) patients having severe OMR (MRI SEV-ECHO SEV) and 135 (69%) patients having moderate OMR (MRI MOD-ECHO MOD). The remaining 61 (24%) individuals had discordant findings (MRI SEV-ECHO MOD or MRI MOD-ECHO SEV) between the 2 techniques. The majority of these differences in OMR classification were observed in patients with late systolic or multiple jets (both κ<0.2). Patients with eccentric jets showed moderate agreement (κ=0.53; 95% confidence interval, 0.41-0.64). In contrast, a very good agreement (κ=0.90; 95% confidence interval, 0.82-0.98) was observed in a combination of holosystolic, central, and single jet. During a median follow-up of 5.0 years (interquartile range, 3.5-6.0 years), 38 (15%) patients died and 106 (41%) either died or developed indication for mitral valve surgery. In separate Cox regression analyses, the MRI-derived left ventricular end-systolic volume index, RV, and OMR category (severe versus moderate), and the ECHO-derived OMR category were independent predictors of all-cause mortality (all P<0.05). The MRI-derived RV showed the largest area under the curve to predict mortality (0.72) or its combination with the development of indication for mitral valve surgery (0.83).The findings of the present study suggest that the MRI-derived assessment of OMR can better identify patients with severe OMR and adverse outcome than ECHO-derived integrative approach warranting close follow-up and perhaps, early mitral valve surgery.
CCR6 Defines Memory B Cell Precursors in Mouse and Human Germinal Centers, Revealing Light-Zone Location and Predominant Low Antigen Affinity
Authors: Dan Suan, Nike J. Kräutler, Jesper L.V. Maag, Danyal Butt, Katherine Bourne, Jana R. Hermes, Danielle T. Avery, Clara Young, Aaron Statham, Michael Elliott, Marcel E. Dinger, Antony Basten, Stuart G. Tangye, Robert Brink
Journal: Immunity (2017)